---
document_datetime: 2023-09-21 18:41:25
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zinbryta-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zinbryta-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3636679
conversion_datetime: 2025-12-28 15:19:10.360017
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zinbryta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|---------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10518 /201705  | Periodic Safety Update EU Single assessment - daclizumab                  | 25/01/2018 product                  | 04/06/2018                                     | SmPC, PL                         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10518/201705. |
| IA/0016              | A.7 - Administrative change - Deletion of manufacturing sites             | 31/01/2018                          | n/a                                            |                                  |                                                                                                                                            |
| IB/0015              | A.3 - Administrative change - Change in name of the AS or of an excipient | 08/01/2018                          | 04/06/2018                                     | SmPC, Labelling and              |                                                                                                                                            |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |               | PL                           |                                                                                           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------------|-------------------------------------------------------------------------------------------|
| A20/0010  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 9 June 2017 the opinion of the European Medicines Agency further to serious cases of liver injury including a fatal case in the authorised settings of use despite adherence to the risk minimisation measures recommended, including the liver function monitoring. The CHMP was requested to assess the impact of this new data on the benefit-risk balance of Zinbryta (daclizumab) and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee. The notification for the procedure is appended to this recommendation. product | 09/11/2017 | 08/01/2018 no | SmPC, Annex II and PL longer | Please refer to the assessment report: Zinbryta EMEA/H/A-20/1456/C/003862/0010 authorised |
| IA/0014/G | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/12/2017 | n/a           |                              |                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0013             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/09/2017   | n/a           |             | authorised                                                                                                                                                                                                                                                                                                                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009             | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/08/2017   | n/a           |             |                                                                                                                                                                                                                                                                                                                                           |
| IA/0011             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/07/2017   | n/a           | longer      |                                                                                                                                                                                                                                                                                                                                           |
| II/0007             | Update of sections 4.4 and 4.8 of the SmPC in order to add autoimmune haemolytic anaemia with frequency 'uncommon' and to include a warning concerning symptoms of this adverse drug reaction based on reported post-marketing cases. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder took the opportunity to implement minor editorial amendments throughout the Product Information. The RMP version 5.1 has been approved. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 09/06/2017   | 08/01/2018 no | SmPC and PL | Autoimmune haemolytic anaemia was reported in <1% of patients treated with Zinbryta in clinical studies. If a patient develops signs or symptoms of autoimmune haemolytic anaemia (e.g. pallor, fatigue, dark urine, jaundice, shortness of breath), the prescriber should consider referring to a specialist and discontinuing Zinbryta. |
| PSUSA/10518 /201611 | Periodic Safety Update EU Single assessment - daclizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/06/2017   | n/a           |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                         |
| IB/0008             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/05/2017   | n/a           |             |                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IG/0709   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/02/2017   | n/a                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------|
| N/0004    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/01/2017   | 08/01/2018 PL authorised |
| IA/0003/G | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised                                                                                                                                                                                                                                                                     | 14/09/2016   | n/a longer               |
| IA/0002/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits Medicinal product | 14/09/2016   | n/a no                   |

<div style=\"page-break-after: always\"></div>

| N/0001   | Update of the package leaflet with revised contact details of the local representatives for Romania and Norway. In addition, the MAH took the opportunity to make minor linguistic amendments to the French labelling and package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 04/08/2016   | 08/01/2018   | PL   | authorised   |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|--------------|

Medicinal product no longer authorised